aromasil has been researched along with androstenedione in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 11 (39.29) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barmade, MA; Murumkar, PR; Tamboli, RS; Yadav, MR | 1 |
| Benedetti, MS; Coombes, RC; Di Salle, E; Evans, TR; Lassus, M; Ornati, G; Pianezzola, E | 1 |
| Coombes, RC; di Salle, E; Evans, TR; Giudici, D; Lassus, M; Ornati, G | 1 |
| di Salle, E; Giudici, D; Ornati, G; Panzeri, A; Zaccheo, T | 1 |
| Briatico, G; D'Alessio, R; Di Salle, E; Giudici, D; Lombardi, P; Ornati, G; Villa, V | 1 |
| Briatico, G; di Salle, E; Giudici, D; Ornati, G | 1 |
| Briatico, G; di Salle, E; Giudici, D; Ornati, G; Zaccheo, T | 1 |
| Anker, G; Di Salle, E; Dowsett, M; Geisler, J; King, N; Lønning, PE; Ornati, G | 1 |
| Lønning, PE | 1 |
| Anker, GB; Johannessen, DC; Lien, EA; Lonning, PE; Refsum, H; Ueland, PM | 1 |
| Blijham, GH; de Jong, PC | 1 |
| Bonneterre, J; Feutrie, ML | 1 |
| Harvey, HA; Santen, RJ | 1 |
| Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N | 1 |
| Auvray, P; Bichat, F; Genne, P | 1 |
| de Crémoux, P | 1 |
| Kerbrat, P; Lefeuvre, C | 1 |
| Buzdar, A; Howell, A | 1 |
| Lombardi, P | 1 |
| Delozier, T; Khayat, D; Spano, JP | 1 |
| Baelde, HJ; Bovée, JV; Cleton-Jansen, AM; Hogendoorn, PC; Karperien, M; van Beerendonk, HM | 1 |
| Chen, S; Wang, X | 1 |
| Dutta, U; Pant, K | 1 |
| Csákvári, E; Gyenes, A; Hoyk, Z; Kóti, J; Paragi, G; Párducz, A; Pfoh, R; Rühl, S; Szájli, A; Wölfling, J | 1 |
| Chen, S; Hong, Y; Rashid, R | 1 |
| Gallicchio, L; Helzlsouer, KJ; Macdonald, R; Rushovich, E; Wood, B | 1 |
| Martí, S; Viciano, I | 1 |
| Goedegebuure, WJ; Hokken-Koelega, ACS | 1 |
14 review(s) available for aromasil and androstenedione
| Article | Year |
|---|---|
Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Female; Humans; Models, Molecular; Molecular Structure | 2015 |
Exemestane (FCE 24304), a new steroidal aromatase inhibitor.
Topics: 5-alpha Reductase Inhibitors; Androgens; Androstadienes; Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Humans; Lyases; Receptors, Steroid | 1992 |
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Topics: Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause | 1998 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estrogen Antagonists; Estrone; Female; Humans; Letrozole; Nitriles; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
[Preclinical evaluation of aromatase inhibitors antitumor activity].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fadrozole; Female; Humans; Letrozole; Models, Animal; Nitriles; Rats; Structure-Activity Relationship; Triazoles | 2000 |
[Aromatase inhibitors: pharmacological aspects].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting | 2001 |
Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
Topics: Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent | 2002 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Menopause; Nitriles; Triazoles | 2004 |
Aromatase inhibitors: past, present and future in breast cancer therapy.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles | 2008 |
4 trial(s) available for aromasil and androstenedione
| Article | Year |
|---|---|
Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
Topics: Aged; Androstadienes; Androstenedione; Aromatase Inhibitors; Dehydroepiandrosterone; Estrogens; Female; Follicle Stimulating Hormone; Headache; Humans; Luteinizing Hormone; Menopause; Middle Aged; Testosterone | 1992 |
Exemestane (FCE 24304), a new steroidal aromatase inhibitor.
Topics: 5-alpha Reductase Inhibitors; Androgens; Androstadienes; Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Humans; Lyases; Receptors, Steroid | 1992 |
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Topics: Administration, Oral; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carbon Radioisotopes; Estradiol; Estrogens; Estrone; Female; Humans; Postmenopause; Tritium | 1998 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Testosterone; Triazoles | 2011 |
11 other study(ies) available for aromasil and androstenedione
| Article | Year |
|---|---|
Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Androstadienes; Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Cell Division; Dose-Response Relationship, Drug; Endocrine Glands; Female; Luteinizing Hormone; Mammary Neoplasms, Experimental; Organ Size; Ovariectomy; Pargyline; Prolactin; Rats | 1991 |
4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione.
Topics: Androstadienes; Androstenedione; Animals; Aromatase Inhibitors; Female; Male; Pregnancy; Rats; Rats, Inbred Strains | 1990 |
Novel irreversible aromatase inhibitors.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Animals; Aromatase Inhibitors; Female; Gonadotropins, Equine; Humans; In Vitro Techniques; Kinetics; Microsomes; Ovary; Pargyline; Placenta; Rats; Rats, Inbred Strains | 1990 |
Aromatase inhibition and experimental antitumor activity of FCE 24304, MDL 18962 and SH 489.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Androstadienes; Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Female; Humans; Luteinizing Hormone; Male; Mammary Neoplasms, Experimental; Microsomes; Orchiectomy; Ovary; Pargyline; Placenta; Pregnancy; Rats; Rats, Inbred Strains; Reference Values | 1989 |
Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Creatinine; Enzyme Inhibitors; Estrogen Antagonists; Homocysteine; Humans; Postmenopause; Vitamins | 1999 |
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Topics: Adult; Aged; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Dose-Response Relationship, Drug; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2005 |
Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor.
Topics: Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Stability; Female; Humans; Proteasome Endopeptidase Complex | 2006 |
Computer-aided structure analysis of an epimerized dehydroepiandrosterone derivative and its biological effect in a model of reactive gliosis.
Topics: Androstadienes; Androstenedione; Animals; Aromatase; Aromatase Inhibitors; Crystallography, X-Ray; Dehydroepiandrosterone; Glial Fibrillary Acidic Protein; Gliosis; Male; Molecular Sequence Data; Molecular Structure; Rats; Rats, Wistar | 2010 |
Binding features of steroidal and nonsteroidal inhibitors.
Topics: Amino Acids; Androgens; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Catalytic Domain; Estrogens; Estrone; Female; Humans; Letrozole; Mutagenesis, Site-Directed; NADPH-Ferrihemoprotein Reductase; Neoplasms, Hormone-Dependent; Nitriles; Protein Conformation; Structure-Activity Relationship; Triazoles | 2011 |
Theoretical Study of the Mechanism of Exemestane Hydroxylation Catalyzed by Human Aromatase Enzyme.
Topics: Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Hydroxylation; Molecular Docking Simulation; Thermodynamics | 2016 |
Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Age Determination by Skeleton; Androstadienes; Androstenedione; Aromatase Inhibitors; Body Height; Bone Development; Child; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Male; Puberty; Puberty, Precocious | 2019 |